

Adverse Event Reporting Contact List

| Country | Group Email |
|--------------------------|--------------------------------|
| Afghanistan | PK-Phv@lilly.com |
| Albania | PHV_CENTRE_SEE@lilly.com |
| Algeria | PV_NWA@LILLY.COM |
| Angola | farmacovigilancia_pt@lilly.com |
| Argentina | lacmass_phv@lilly.com |
| Armenia | LillyRu_Safety@lilly.com |
| Aruba | lacmass_phv@lilly.com |
| Australia | AU_Drug_Safety@lilly.com |
| Austria | austria_regulatory@lilly.com |
| Azerbaijan | LillyRu_Safety@lilly.com |
| Bahamas | lacmass_phv@lilly.com |
| Bangladesh | IN_GPS@lilly.com |
| Belarus | LillyRu_Safety@lilly.com |
| Belgium | Safety_Bemail-Drug@lilly.com |
| Benin | ADE_ZA@lilly.com |
| Bolivia | lacmass_phv@lilly.com |
| Bosnia-Herzegovina | PHV_CENTRE_SEE@lilly.com |
| Botswana | ADE_ZA@lilly.com |
| Brazil (BRC) | farmacovigilancia_br@lilly.com |
| Brunei | AMS1_PHV-CENTRE@lilly.com |
| Bulgaria | PHV_CENTRE_SEE@lilly.com |
| Burkina Faso | ADE_ZA@lilly.com |
| Burundi | ADE_ZA@lilly.com |
| Cameroon | ADE_ZA@lilly.com |
| Canada | pv@lilly.com |
| Cayman Islands | lacmass_phv@lilly.com |
| Central African Republic | ADE_ZA@lilly.com |
| Chad | ADE_ZA@lilly.com |
| Chile | lacmass_phv@lilly.com |
| China | cn_pv@lilly.com |
| Colombia | lacmass_phv@lilly.com |

Adverse Event Reporting Contact List

| Country | Group Email |
|------------------------------|--------------------------------------|
| Comoros | ADE_ZA@lilly.com |
| Congo Republic | ADE_ZA@lilly.com |
| Costa Rica | lacmass_phv@lilly.com |
| Croatia | PHV_CENTRE_SEE@lilly.com |
| Curazao | lacmass_phv@lilly.com |
| Cyprus | PHV_CENTRE_SEE@lilly.com |
| Czech Republic | phv_czsk@lilly.com |
| Democratic Republic of Congo | ADE_ZA@lilly.com |
| Denmark | DK_PhV@lilly.com |
| Djibouti | ADE_ZA@lilly.com |
| Dominican Republic | lacmass_phv@lilly.com |
| Ecuador | lacmass_phv@lilly.com |
| Egypt | PHV_EMAIL_EGMAIL-MENA@LILLY.COM |
| El Salvador | lacmass_phv@lilly.com |
| Equatorial Guinea | ADE_ZA@lilly.com |
| Eritrea | ADE_ZA@lilly.com |
| Estonia (Baltic States) | LV_LT_EE_Safety@lilly.com |
| Ethiopia | ADE_ZA@lilly.com |
| Finland | laaketurva@lilly.com |
| France | FR_Paris_Pharmacovigilance@lilly.com |
| Gabon | ADE_ZA@lilly.com |
| Gambia | ADE_ZA@lilly.com |
| Georgia | LillyRu_Safety@lilly.com |
| Germany | HG_DEMAIL-Safety@lilly.com |
| Ghana | ADE_ZA@lilly.com |
| Greece | GR_PHARMACOVIGILANCE@lilly.com |
| Guatemala | lacmass_phv@lilly.com |
| Guinea | ADE_ZA@lilly.com |
| Haiti | lacmass_phv@lilly.com |
| Honduras | lacmass_phv@lilly.com |
| Hong Kong | AE_HK@lilly.com |

Adverse Event Reporting Contact List

| Country | Group Email |
|---------------------------|--|
| Hungary | adverzeset_hungary@lilly.com |
| Iceland | DK_PhV@lilly.com |
| India | IN_GPS@lilly.com |
| Indonesia | AMS1_PHV-CENTRE@lilly.com |
| Iran | PV-MEA@lilly.com |
| Iraq | PV-MEA@lilly.com |
| Ireland | UK_TEAM_GBMAIL-GPS@lilly.com |
| Israel | REPORT_ILMAIL-AE@LILLY.COM |
| Italy | farmacovigilanza@lilly.com |
| Ivory Coast | ADE_ZA@lilly.com |
| Jamaica | lacmass_phv@lilly.com |
| Japan | GPSJ_JPMAIL-LRLJ@LILLY.COM |
| Jordan | PV-MEA@lilly.com |
| Kazakhstan | LILLY_SAFETY_CARAGA@LILLY.COM |
| Kenya | ADE_ZA@lilly.com |
| Kuwait | PV-MEA@lilly.com |
| Kyrgyzstan | LillyRu_Safety@lilly.com |
| Latvia (Baltic States) | LV_LT_EE_Safety@lilly.com |
| Lebanon | PV-MEA@lilly.com |
| Lesotho | ADE_ZA@lilly.com |
| Liberia | ADE_ZA@lilly.com |
| Libya | PHV_EMAIL_EGMAIL-MENA@LILLY.COM |
| Liechtenstein | SWITZ_CHMAIL-PHARMACOVIGILANCE@LILLY.COM |
| Lithuania (Baltic States) | LV_LT_EE_Safety@lilly.com |
| Luxembourg | Safety_Bemail-Drug@lilly.com |
| Macau | AE_HK@lilly.com |
| Madagascar | ADE_ZA@lilly.com |
| Malawi | ADE_ZA@lilly.com |

Adverse Event Reporting Contact List

| Country | Group Email |
|-----------------|--------------------------------|
| Malaysia | AMS1_PHV-CENTRE@lilly.com |
| Mali | ADE_ZA@lilly.com |
| Malta | PHV_CENTRE_SEE@lilly.com |
| Mauritania, | ADE_ZA@lilly.com |
| Mauritius | ADE_ZA@lilly.com |
| Mexico | mx_farmacovigilancia@lilly.com |
| Moldova | PHV_CENTRE_SEE@lilly.com |
| Mongolia | LillyRu_Safety@lilly.com |
| Morocco | PV_NWA@LILLY.COM |
| Mozambique | farmacovigilancia_pt@lilly.com |
| Myanmar | AMS1_PHV-CENTRE@lilly.com |
| Namibia | ADE_ZA@lilly.com |
| Nepal | IN_GPS@lilly.com |
| Netherlands | dso.nl@lilly.com |
| New Zealand | AU_drug_safety@lilly.com |
| Nicaragua | lacmass_phv@lilly.com |
| Niger | ADE_ZA@lilly.com |
| Nigeria | ADE_ZA@lilly.com |
| North Macedonia | PHV_CENTRE_SEE@lilly.com |
| Norway | DK_PhV@lilly.com |
| Oman | PV-MEA@lilly.com |
| Pakistan | PK-Phv@lilly.com |
| Palestine | PV-MEA@lilly.com |
| Panama | lacmass_phv@lilly.com |
| Paraguay | lacmass_phv@lilly.com |
| Peru | lacmass_phv@lilly.com |
| Philippines | AMS1_PHV-CENTRE@lilly.com |
| Poland | pl_pharmacovigilance@lilly.com |
| Portugal | farmacovigilancia_pt@lilly.com |
| Puerto Rico | mailindata_gsmtindy@lilly.com |

Adverse Event Reporting Contact List

| Country | Group Email |
|--------------|--|
| Qatar | PV-MEA@lilly.com |
| Romania | PHV_CENTRE_SEE@lilly.com |
| Russia | LillyRu_Safety@lilly.com |
| Rwanda | ADE_ZA@lilly.com |
| Saudi Arabia | Saudi_Pharmacovigilance@lilly.com |
| Senegal | ADE_ZA@lilly.com |
| Serbia | PHV_CENTRE_SEE@lilly.com |
| Seychelles | ADE_ZA@lilly.com |
| Sierra Leone | ADE_ZA@lilly.com |
| Singapore | AMS1_PHV-CENTRE@lilly.com |
| Slovakia | phv_czsk@lilly.com |
| Slovenia | PHV_CENTRE_SEE@lilly.com |
| South Africa | ADE_ZA@lilly.com |
| South Korea | safetykorea@lilly.com |
| South Sudan | ADE_ZA@lilly.com |
| Spain | farmacovigilanciaes@lilly.com |
| Sri Lanka | IN_GPS@lilly.com |
| St. Croix | lacmass_phv@lilly.com |
| St. Marteen | lacmass_phv@lilly.com |
| St. Thomas | lacmass_phv@lilly.com |
| Sudan | PHV_EMAIL_EGMAIL-MENA@LILLY.COM |
| Swaziland | ADE_ZA@lilly.com |
| Sweden | DK_PhV@lilly.com |
| Switzerland | SWITZ_CHMAIL-PHARMACOVIGILANCE@LILLY.COM |
| Syria | PV-MEA@lilly.com |
| Taiwan | inbox_twmail-safety@lilly.com |
| Tajikistan | LillyRu_Safety@lilly.com |
| Tanzania | ADE_ZA@lilly.com |
| Thailand | AMS1_PHV-CENTRE@lilly.com |

Adverse Event Reporting Contact List

| Country | Group Email |
|----------------------|---|
| Togo | ADE_ZA@lilly.com |
| Trinidad and Tobago | lacmass_phv@lilly.com |
| Tunisia | PV_NWA@LILLY.COM |
| Turkey | pharmacovigilance_turkey@lilly.com |
| Turkmenistan | LillyRu_Safety@lilly.com |
| Uganda | ADE_ZA@lilly.com |
| Ukraine | lillyubm_safety@lilly.com |
| United Arab Emirates | PV-MEA@lilly.com |
| United Kingdom | UK_TEAM_GBMAIL-GPS@lilly.com |
| United States | <p>For most US vendors: Call The Lilly Answers Center at 1-800 LillyRx (1-800-545-5979)</p> <p>For US Market Research, social listening, and specific PSPs: report to mailindata_gsmtindy@lilly.com</p> <p>For US reconciliation: send to BA_GPS@lilly.com</p> |
| Uruguay | lacmass_phv@lilly.com |
| Uzbekistan | LillyRu_Safety@lilly.com |
| Venezuela | phv_lacmass@lilly.com |
| Vietnam | AMS1_PHV-CENTRE@lilly.com |
| Yemen | PV-MEA@lilly.com |
| Zambia | ADE_ZA@lilly.com |
| Zimbabwe | ADE_ZA@lilly.com |